Alane P. Barnes - 12 Dec 2025 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Signature
/s/ Alane P. Barnes
Issuer symbol
BCRX
Transactions as of
12 Dec 2025
Net transactions value
-$226,904
Form type
4
Filing time
16 Dec 2025, 16:13:10 UTC
Previous filing
03 Dec 2025
Next filing
19 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Barnes Alane P Chief Legal Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM /s/ Alane P. Barnes 16 Dec 2025 0001584348

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Tax liability $64,648 -8,540 -2.5% $7.57 336,936 12 Dec 2025 Direct F1
transaction BCRX Common Stock Sale $162,256 -21,210 -6.3% $7.65 315,726 15 Dec 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.
F2 This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.